Journal Home > Volume 12 , Issue 5

In a previous study from our laboratory, fucoxanthin purified from brown algae, Sargassum wightii Greville has found to exhibit antioxidant activity and inhibition of angiotensin-I-converting enzyme (ACE) in vitro. The present study aims in understanding the protective effect of fucoxanthin purified from S. wightii against diabetes with hypertension in in vivo. Diabetes and hypertension were induced in rat by streptozotocin and sodium chloride treatment, respectively. In diabetes with hypertension rat, the blood pressure was increased along with hyperglycemia. Administration of fucoxanthin significantly reduced the blood pressure and ACE activity in diabetes with hypertension rat. Furthermore, administration of fucoxanthin significantly reduced the hyperglycemic state. The activity of various enzymes in the liver (hexokinase, glucose-6-phosphate dehydrogenase, glucose-6-phosphatase and fructose-1, 6-phosphatase) and serum (creatine kinase) were normalized to that of control level. The level of glycogen, glycoprotein component and lipid profile were equivalent to control level by fucoxanthin administration in diabetes with hypertension rats. Fucoxanthin ameliorated the oxidative stress by preserving the endogenous antioxidant levels in diabetes with hypertension rats. Also, the pancreatic histological integrity was similar to that of control level in diabetes with hypertension rats by fucoxanthin treatment. Altogether, fucoxanthin showed dual antidiabetic and antihypertensive activity in vivo.


menu
Abstract
Full text
Outline
About this article

Dual antidiabetic and antihypertensive activity of fucoxanthin isolated from Sargassum wightii Greville in in vivo rat model

Show Author's information Vijayan RajiaChitra LoganathanaThiyagarajan RameshbPalvannan Thayumanavana( )
Department of Biochemistry, Periyar University, Salem, Tamil Nadu 636011, India
Department of Basic Medical Sciences, College of Medicine, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Kingdom of Saudi Arabia

Peer review under responsibility of KeAi Communications Co., Ltd.

Abstract

In a previous study from our laboratory, fucoxanthin purified from brown algae, Sargassum wightii Greville has found to exhibit antioxidant activity and inhibition of angiotensin-I-converting enzyme (ACE) in vitro. The present study aims in understanding the protective effect of fucoxanthin purified from S. wightii against diabetes with hypertension in in vivo. Diabetes and hypertension were induced in rat by streptozotocin and sodium chloride treatment, respectively. In diabetes with hypertension rat, the blood pressure was increased along with hyperglycemia. Administration of fucoxanthin significantly reduced the blood pressure and ACE activity in diabetes with hypertension rat. Furthermore, administration of fucoxanthin significantly reduced the hyperglycemic state. The activity of various enzymes in the liver (hexokinase, glucose-6-phosphate dehydrogenase, glucose-6-phosphatase and fructose-1, 6-phosphatase) and serum (creatine kinase) were normalized to that of control level. The level of glycogen, glycoprotein component and lipid profile were equivalent to control level by fucoxanthin administration in diabetes with hypertension rats. Fucoxanthin ameliorated the oxidative stress by preserving the endogenous antioxidant levels in diabetes with hypertension rats. Also, the pancreatic histological integrity was similar to that of control level in diabetes with hypertension rats by fucoxanthin treatment. Altogether, fucoxanthin showed dual antidiabetic and antihypertensive activity in vivo.

Keywords: Hypertension, Diabetes, Oxidative stress, Fucoxanthin, Angiotensin-I-converting enzyme

References(50)

[1]

C. Lourenço-Lopes, P. Garcia-Oliveira, M. Carpena, et al., Scientific approaches on extraction, purification and stability for the commercialization of fucoxanthin recovered from brown algae, Foods 9 (2020) 1113. https://doi.org/10.3390/foods9081113.

[2]

Y. Zhang, W. Xu, X. Huang, et al., Fucoxanthin ameliorates hyperglycemia, hyperlipidemia and insulin resistance in diabetic mice partially through IRS-1/PI3K/Akt and AMPK pathways, J. Funct. Foods 48 (2018) 515-524. https://doi.org/10.1016/j.jff.2018.07.048.

[3]

M. Bilal, H.M. Iqbal, Biologically active macromolecules: extraction strategies, therapeutic potential and biomedical perspective, Int. J. Biol. Macromol. 151 (2020) 1-18. https://doi.org/10.1016/j.ijbiomac.2020.02.037.

[4]

M.C. Kang, S.H. Lee, W.W. Lee, et al., Protective effect of fucoxanthin isolated from Ishige okamurae against high-glucose induced oxidative stress in human umbilical vein endothelial cells and zebrafish model, J. Funct. Foods 11 (2014) 304-312. https://doi.org/10.1016/j.jff.2014.09.007.

[5]

M. Ohishi, Hypertension with diabetes mellitus: physiology and pathology, Hypertens. Res. 41 (2018) 389-393. https://doi.org/10.1038/s41440-018-0034-4.

[6]

J.R. Sowers, M. Epstein, E.D. Frohlich, Diabetes, hypertension, and cardiovascular disease: an update, Hypertension 37 (2001) 1053-1059. https://doi.org/10.1161/01.HYP.37.4.1053.

[7]

G. Govindarajan, J.R. Sowers, C.S. Stump, Hypertension and diabetes mellitus, European Cardiology 2 (2006) 1-7.

[8]

J.R. Petrie, T.J. Guzik, R.M. Touyz, Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms, Can. J. Cardiol. 34 (2018) 575-584. https://doi.org/10.1016/j.cjca.2017.12.005.

[9]

V. Raji, C. Loganathan, G. Sadhasivam, et al., Purification of fucoxanthin from Sargassum wightii Greville and understanding the inhibition of angiotensin 1-converting enzyme: an in vitro and in silico studies, Int. J. Biol. Macromol. 148 (2020) 696-703. https://doi.org/10.1016/j.ijbiomac.2020.01.140.

[10]

N. Orie, N. Anyaegbu, Nifedipine effectively lowers salt-induced high blood pressure in diabetic rats, General Pharmacology: The Vascular System 32 (1999) 471-474. https://doi.org/10.1016/S0306-3623(98)00244-4.

[11]

S. Parasuraman, R. Raveendran, Measurement of invasive blood pressure in rats, J. Pharmacol. Pharmacother. 3 (2012) 172. https://doi.org/10.4103/0976-500X.95521.

[12]

N. Brandstrup, J. Kirk, C. Bruni, The hexokinase and phosphoglucoisomerase activities of aortic and pulmonary artery tissue in individuals of various ages, J. Gerontol. 12 (1957) 166-171. https://doi.org/10.1093/geronj/12.2.166.

[13]

K. Hikaru, O. Toshitsugu, Pathological occurrence of glucose-6-phosphatase in serum in liver diseases, Clin. Chim. Acta 4 (1959) 554-561. https://doi.org/10.1016/0009-8981(59)90165-2.

[14]

H.A. Ells, H. Kirkman, A colorimetric method for assay of erythrocytic glucose-6-phosphate dehydrogenase, P. Soc. Exp. Biol. Med. 106 (1961) 607-609. https://doi.org/10.3181/00379727-106-26418.

[15]

J.M. Gancedo, C. Gancedo, Fructose-1, 6-diphosphatase, phosphofructokinase and glucose-6-phosphate dehydrogenase from fermenting and non fermenting yeasts, Archiv für Mikrobiologie 76 (1971) 132-138. https://doi.org/10.1007/BF00411787.

[16]

S. Seifter, S. Dayton, B. Novic, et al., The estimation of glycogen with the anthrone reagent, Arch. Biochem. 25 (1950) 191-200.

[17]

P. Niebes, Determination of enzymes and degradation products of glycosaminoglycan metabolism in the serum of healthy and varicose subjects, Clin. Chim. Acta 42 (1972) 399-408. https://doi.org/10.1016/0009-8981(72)90105-2.

[18]

S.T. Omaye, J.D. Turnbull, H.E. Sauberlich, Selected methods for the determination of ascorbic acid in animal cells, tissues, and fluids, Methods Enzymol. 62 (1979) 3-11. https://doi.org/10.1016/0076-6879(79)62181-x.

[19]

G.L. Ellman, Tissue sulfhydryl groups, Arch. Biochem. Biophys. 82 (1959) 70-77. https://doi.org/10.1016/0003-9861(59)90090-6.

[20]

P. Kakkar, B. Das, P. Viswanathan, A modified spectrophotometric assay of superoxide dismutase, Indian J. Biochem. Biophys. 21 (1984) 130-132.

[21]

M.H. Hadwan, New method for assessment of serum catalase activity, Indian J. Sci. Techn. 9 (2016) 1-5. https://doi.org/10.17485/ijst/2016/v9i4/80499.

[22]

J.T. Rotruck, A.L. Pope, H.E. Ganther, et al., Selenium: biochemical role as a component of glutathione peroxidase, Science 179 (1973) 588-590. https://doi.org/10.1126/science.179.4073.588.

[23]

S. Al-Quraishy, M.A. Dkhil, A.E.A. Moneim, Anti-hyperglycemic activity of selenium nanoparticles in streptozotocin-induced diabetic rats, Int. J. Nanomed. 10 (2015) 6741. https://doi.org/10.2147/IJN.S91377.

[24]

M.M. Rahman, H.S. Kwon, M.J. Kim, et al., Melatonin supplementation plus exercise behavior ameliorate insulin resistance, hypertension and fatigue in a rat model of type 2 diabetes mellitus, BioMed. Pharmacother. 92 (2017) 606-614. https://doi.org/10.1016/j.biopha.2017.05.035.

[25]

F.C. Luft, L.I. Rankin, A.P. Evan, et al., Blood pressure of alloxan diabetic rats at regular and high salt intake, Clin. Exp. Hypertens. 3 (1981) 509-522. https://doi.org/10.3109/10641968109033679.

[26]

H. Salahdeen, A. Alada, Cardiovascular response to angiotensin Ⅱ and captopril in normal and diabetic rats loaded with salt, J. Med. Sci. 7 (2007) 187-194. https://doi.org/10.3923/JMS.2007.187.194.

[27]

Y. Takagi, H. Kadowaki, I. Kobayashi, et al., Effects of high-sodium intake on systemic blood pressure and vascular responses in spontaneously diabetic WBN/Kob-Leprfa/fa rats, Clin. Exp. Pharmacol. Physiol. 44 (2017) 305-312. https://doi.org/10.1111/1440-1681.12700.

[28]

K. Ikeda, A. Kitamura, H. Machida, et al., Effect of Undaria pinnatifida (Wakame) on the development of cerebrovascular diseases in stroke-prone spontaneously hypertensive rats, Clin. Exp. Pharmacol. Physiol. 30 (2003) 44-48. https://doi.org/10.1046/j.1440-1681.2003.03786.x.

[29]

M.H. Shishavan, R.H. Henning, A. van Buiten, et al., Metformin improves endothelial function and reduces blood pressure in diabetic spontaneously hypertensive rats independent from glycemia control: comparison to vildagliptin, Sci. Rep. 7 (2017) 1-12. https://doi.org/10.1038/s41598-017-11430-7.

[30]

H.C. Ou, W.C. Chou, P.M. Chu, et al., Fucoxanthin protects against oxLDL‐induced endothelial damage via activating the AMPK‐Akt‐CREB‐PGC1α pathway, Mol. Nutr. Food Res. 63 (2019) 1801353. https://doi.org/10.1002/mnfr.201801353.

[31]

Y.Q. Zhao, L. Zhang, G.X. Zhao, et al., Fucoxanthin attenuates doxorubicin-induced cardiotoxicity via anti-oxidant and anti-apoptotic mechanisms associated with p38, JNK and p53 pathways, J. Funct. Foods 62 (2019) 103542. https://doi.org/10.1016/j.jff.2019.103542.

[32]

V. Ramachandran, R. Saravanan, P. Senthilraja, Antidiabetic and antihyperlipidemic activity of asiatic acid in diabetic rats, role of HMG CoA: in vivo and in silico approaches, Phytomed. 21 (2014) 225-232. https://doi.org/10.1016/j.phymed.2013.08.027.

[33]

S. Penislusshiyan, L. Chitra, I. Ancy, et al., Novel antioxidant astaxanthin-S-allyl cysteine biconjugate diminished oxidative stress and mitochondrial dysfunction to triumph diabetes in rat model, Life Sci. 245 (2020) 117367. https://doi.org/10.1016/j.lfs.2020.117367.

[34]

H. Park, M. Lee, Y. Park, et al., Beneficial effects of Undaria pinnatifida ethanol extract on diet-induced-insulin resistance in C57BL/6J mice, Food Chem. Toxicol. 49 (2011) 727-733. https://doi.org/10.1016/j.fct.2010.11.032.

[35]

L. Cohen-Forterre, J. Andre, G. Mozere, et al., Kidney sialidase and sialyltransferase activities in spontaneously and experimentally diabetic rats: influence of insulin and sorbinil treatments, Biochem. Pharmacol. 40 (1990) 507-513. https://doi.org/10.1016/0006-2952(90)90549-z.

[36]

Z. Wang, J.M. do Carmo, N. Aberdein, et al., Synergistic interaction of hypertension and diabetes in promoting kidney injury and the role of endoplasmic reticulum stress, Hypertension 69 (2017) 879-891. https://doi.org/10.1161/HYPERTENSIONAHA.116.08560.

[37]

T. Tsukui, K. Konno, M. Hosokawa, et al., Fucoxanthin and fucoxanthinol enhance the amount of docosahexaenoic acid in the liver of KKAy obese/diabetic mice, J. Agric. Food Chem. 55 (2007) 5025-5029. https://doi.org/10.1021/jf070110q.

[38]

H. Maeda, T. Tsukui, T. Sashima, et al., Seaweed carotenoid, fucoxanthin, as a multi-functional nutrient, Asia Pac. J. Clin. Nutr. 17 (2008).

[39]

H. Maeda, M. Hosokawa, T. Sashima, et al., Anti-obesity and anti-diabetic effects of fucoxanthin on diet-induced obesity conditions in a murine model, Mol. Med. Rep. 2 (2009) 897-902. https://doi.org/10.3892/mmr_00000189.

[40]

J. Peng, J.P. Yuan, C.F. Wu, et al., Fucoxanthin, a marine carotenoid present in brown seaweeds and diatoms: metabolism and bioactivities relevant to human health, Marine Drugs 9 (2011) 1806-1828. https://doi.org/10.3390/md9101806.

[41]

H. Nishino, Cancer prevention by carotenoids, Mutat. Res. 402 (1998) 159-163. https://doi.org/10.1016/s0027-5107(97)00293-5.

[42]

R. Sangeetha, N. Bhaskar, V. Baskaran, Comparative effects of β-carotene and fucoxanthin on retinol deficiency induced oxidative stress in rats, Mol. Cell. Biochem. 331 (2009) 59. https://doi.org/10.1007/s11010-009-0145-y.

[43]

R.K. Sangeetha, N. Bhaskar, V. Baskaran, Fucoxanthin restrains oxidative stress induced by retinol deficiency through modulation of Na+ Ka+-ATPase and antioxidant enzyme activities in rats, Eur. J. Nutr. 47 (2008) 432-441. https://doi.org/10.1007/s00394-008-0745-4.

[44]

M. Abidov, Z. Ramazanov, R. Seifulla, et al., The effects of XanthigenTM in the weight management of obese premenopausal women with non-alcoholic fatty liver disease and normal liver fat, Diabetes Obes. Metab. 12 (2010) 72-81. https://doi.org/10.1111/j.1463-1326.2009.01132.x.

[45]

Y.C. Chen, C.Y. Cheng, C.T. Liu, et al., Alleviative effect of fucoxanthin-containing extract from brown seaweed Laminaria japonica on renal tubular cell apoptosis through upregulating Na+/H+ exchanger NHE1 in chronic kidney disease mice, J. Ethnopharmacol. 224 (2018) 391-399. https://doi.org/10.1016/j.jep.2018.06.023.

[46]

C.L. Liu, Y.T. Chiu, M.L. Hu, Fucoxanthin enhances HO-1 and NQO1 expression in murine hepatic BNL CL. 2 cells through activation of the Nrf2/ARE system partially by its pro-oxidant activity, J. Agric. Food Chem. 59 (2011) 11344-11351. https://doi.org/10.1021/jf2029785.

[47]

T. Nomura, M. Kikuchi, A. Kubodera, et al., Proton-donative antioxidant activity of fucoxanthin with 1, 1-diphenyl-2-picrylhydrazyl (DPPH), IUBMB Life 42 (1997) 361-370. https://doi.org/10.1080/15216549700202761.

[48]

X. Yan, Y. Chuda, M. Suzuki, et al., Fucoxanthin as the major antioxidant in Hijikia fusiformis, a common edible seaweed, Biosci. Biotechnol. Biochem. 63 (1999) 605-607. https://doi.org/10.1271/bbb.63.605.

[49]

N.M. Sachindra, E. Sato, H. Maeda, et al., Radical scavenging and singlet oxygen quenching activity of marine carotenoid fucoxanthin and its metabolites, J. Agric. Food Chem. 55 (2007) 8516-8522. https://doi.org/10.1021/jf071848a.

[50]

C.I. Chukwuma, M.G. Matsabisa, M.A. Ibrahim, et al., Medicinal plants with concomitant anti-diabetic and anti-hypertensive effects as potential sources of dual acting therapies against diabetes and hypertension: a review, J. Ethnopharmacol. 235 (2019) 329-360. https://doi.org/10.1016/j.jep.2019.02.024.

Publication history
Copyright
Acknowledgements
Rights and permissions

Publication history

Received: 26 June 2021
Revised: 07 July 2021
Accepted: 06 August 2021
Published: 21 March 2023
Issue date: September 2023

Copyright

© 2023 Beijing Academy of Food Sciences.

Acknowledgements

Acknowledgements

Mr. R. Vijayan acknowledges University Grants Commission, New Delhi, India for the award of Rajiv Gandhi National Fellowship (RGNF-2015-17-SC-TAM-20532) to carry out this study. Dr. L. Chitra acknowledges University Grants Commission, India for the award of Dr. D.S. Kothari Post-Doctoral Fellowship (F.4-2/2006 (BSR)/BL/17-18/0313).

Rights and permissions

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Return